Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278710 | PMC |
| http://dx.doi.org/10.1128/AAC.02008-16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association between antimicrobial resistance mutations and treatment outcomes for infections from 2018 to 2022: a cross-sectional study from Auckland, New Zealand.
Sex Health
December 2024
Virology and Immunology Department, LabPlus, Auckland City Hospital, Auckland, New Zealand.
Background New Zealand has among the highest rates of antimicrobial resistance in Mycoplasma genitalium in the world. The aim of this study was to correlate treatment outcomes with 23S rRNA and parC mutations associated with macrolide and fluroquinolone resistance, respectively, in a cohort of sexual health clinic patients. Methods Laboratory and clinical data were collected for patients with M.
View Article and Find Full Text PDFCyclophostin and Cyclipostins analogues counteract macrolide-induced resistance mediated by erm(41) in Mycobacterium abscessus.
J Biomed Sci
December 2024
CNRS, LISM UMR7255, IMM-FR3479, Aix-Marseille Univ, Marseille, France.
Background: Mycobacterium abscessus is an emerging pathogen causing severe pulmonary infections, particularly in individuals with underlying conditions, such as cystic fibrosis or chronic obstructive pulmonary disease. Macrolides, such as clarithromycin (CLR) or azithromycin (AZM), represent the cornerstone of antibiotherapy against the M. abscessus species.
View Article and Find Full Text PDFVariability of macrolide-resistant profile in complex pulmonary disease.
Antimicrob Agents Chemother
November 2024
Department of Respiratory Medicine, National Hospital Organization, Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.
Article Synopsis
- The study investigated macrolide resistance in 68 patients with complex pulmonary diseases, focusing on how treatment affected resistance profiles.
- Among patients not treated with macrolides, over half (52%) reverted to being susceptible to macrolides, while only a tiny fraction (2%) of those continuing treatment saw similar results.
- The analysis of 30 resistant isolates revealed that seven had shifted to susceptible profiles, with reasons including related strains or reinfections.
Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines.
Int J Gynaecol Obstet
July 2024
Department of Obstetrics and Gynecology, Rotunda Hospital, Dublin, Ireland.
Background: Mycoplasma genitalium is an emerging pathogen, which has been linked to cervicitis, urethritis and pelvic inflammatory disease (PID). With the advent of multiplex polymerase chain reaction (PCR) panels for sexually transmitted infections, it is increasingly being identified in pregnant women.
Objectives: The aim was to review international guidelines, which had explicit recommendations for treatment of M.
Novel Knowledge of Macrolide Resistance in by Azithromycin Exposure.
Microorganisms
January 2024
Department of Clinical Infectious Diseases, Kawasaki Medical School, 577, Matsushima, Kurashiki 701-0192, Japan.
The rise of macrolide-resistant (MRMP), marked by point mutations in the 23S rRNA gene, poses a growing global concern since its initial detection in 2001. The prominence of the A2063G mutation during this emergence remains unexplained. This study aimed to clarify the possibility of detecting MRMP from recent clinical macrolide-susceptible through exposure to azithromycin (AZM), which has a long half-life and was launched immediately before the first MRMP detection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!